Treatment
GLP-1 Receptor Agonists clinical trials
We’re tracking 54 recruiting studies that include GLP-1 Receptor Agonists, each written for real people, not researchers, below.
Recruiting studies
- NCT07091500Recruiting
Exercise and a weight-loss drug for people with obesity
This trial tests whether combining a GLP-1 medication (a type of diabetes drug that also helps with weight loss) with an exercise program can improve physical function in people with obesity. If you are obese and have trouble with daily activities, this study may help you become more mobile and healthier.
St Louis, MissouriAges 50–75 - NCT07012642RecruitingEarly Phase 1
GLP-1 drugs for arm or leg swelling (lymphedema)
This trial tests if a class of diabetes drugs (GLP-1 receptor agonists) can reduce swelling in one arm or leg caused by lymphedema. It may help people who have not found relief from other treatments.
Red Bank, New JerseyAges 18 years+ - NCT06976619RecruitingPhase 2
Blood sugar control and a diabetes drug on insulin production
This study looks at how blood sugar control and a class of drugs called GLP-1 agonists (like Ozempic) affect insulin-making cells in people with type 1 or type 2 diabetes who use insulin.
Rochester, MinnesotaAges 25–70 - NCT06924697Enrolling by invitation
Testing a diabetes drug to help men quit smoking
This study tests if a medication used for type 2 diabetes (GLP-1 receptor agonists) can also reduce smoking in men with diabetes who smoke. If you qualify, you may receive this drug or a standard diabetes pill to see if it helps you smoke less.
Shanghai, Shanghai MunicipalityAges 18–75 - NCT06903923RecruitingPhase 2
Bone health in teens and young adults taking GLP-1 weight loss drugs
This trial looks at how GLP-1 receptor agonist medications (like liraglutide or semaglutide) affect bone health in adolescents and young adults with obesity. It aims to understand if these weight loss drugs have any impact on bone density and metabolism.
Charlottesville, VirginiaAges 12–21 - NCT06889454Recruiting
Heart and blood vessel changes in women with PCOS after treatment
This trial looks at how the heart's blood vessels and certain markers change in women with PCOS when they drink a sugary solution (OGTT). It checks these markers before treatment starts and again 6 and 12 months after, to help understand cardiovascular risk in PCOS.
ChaïdáriAges 18–45 - NCT06839248Recruiting
Fasting before procedures with GLP-1 meds
This study looks at whether people taking weekly GLP-1 medications (like Ozempic or Wegovy) should follow standard fasting rules or a 24-hour clear liquid diet before a procedure. The goal is to find the safest way to prepare.
Melbourne, VictoriaAges 18 years+ - NCT06774079RecruitingPhase 4
GLP-1 drug and diet study for Crohn's disease patients
This study tests a drug that helps with weight loss and blood sugar (called a GLP-1 receptor agonist) combined with a special diet to see if it can improve symptoms in people with mild Crohn's disease. You may join if you have Crohn's, a BMI of 27 or higher, and are already on a stable dose of a TNF blocker.
Miami, FloridaAges 18 years+ - NCT06654219Recruiting
Clear liquids before endoscopy for patients on GLP-1 meds
This study tests whether drinking only clear liquids before an upper endoscopy can reduce leftover stomach contents in people taking GLP-1 medications (like Ozempic or Mounjaro). It may help make the procedure safer.
Houston, TexasAges 18 years+ - NCT06581120Enrolling by invitation
Stomach ultrasound study for diabetes and obesity
This study uses ultrasound to see how GLP-1 RA medications (like Ozempic) affect the stomach in people with type 2 diabetes and obesity. It may help doctors better understand how these medicines work.
Cincinnati, OhioAges 10–25 - NCT06256419Recruiting
Gene testing and exenatide response in Chinese type 2 diabetes patients
This study looks at how certain genes affect the risk of type 2 diabetes and how well the drug exenatide (a GLP-1 receptor agonist) works in Chinese patients. It aims to see if your genetic makeup can predict how you will respond to treatment.
Xuzhou, ChinaAges 25–70 - NCT06324461RecruitingPhase 4
GLP-1 drug to protect heart after non-emergency surgery
This study tests whether a GLP-1 receptor agonist (a medication used for diabetes and weight loss) can reduce heart damage during or after planned non-cardiac surgery. It may help patients with heart risk undergoing intermediate to high-risk procedures.
Hong Kong, Hong Kong SARAges 18 years+ - NCT06132477RecruitingPhase 4
Study of GLP-1 medicines after weight loss surgery
This study looks at what happens when people taking a GLP-1 medication (like Ozempic) either stop or continue it after weight loss surgery. The goal is to learn whether staying on the medicine helps with long-term weight control.
Columbia, MissouriAges 18 years+ - NCT06069622Recruiting
How a gene affects weight-loss treatment response
This study looks at how a weight-loss medication affects people with obesity who may have a specific gene difference (caveolin-1). It aims to understand why some people respond differently to GLP-1 treatments like semaglutide.
Boston, MassachusettsAges 18 years+ - NCT05390892RecruitingPhase 4
Preventing kidney and heart damage in type 2 diabetes
This study tests whether diabetes medicines can help prevent worsening heart and kidney problems in people with type 2 diabetes. You’ll be assigned by chance to one of these medicine types, and your other care will be adjusted for safety.
Huntsville, AlabamaAges 40–80 - NCT05356104RecruitingPhase 2
GLP-1 treatment to slow small blood-vessel brain damage
This Phase 2 study tests whether a GLP-1–like medicine can slow worsening “small vessel” disease changes in the brain and related walking and thinking problems. It aims to see if the treatment can prevent progression in people who already show early brain changes on MRI.
Wenzhou, ZhejiangAges 55–80 - NCT07229170Recruiting
Taste changes and eating habits on weight loss drugs
This study looks at how GLP-1 medications (like semaglutide/Wegovy or tirzepatide/Mounjaro) change your sense of taste and eating habits while losing weight. If you are 18–60, have obesity, and have been taking one of these drugs for at least 12 weeks, you may qualify.
Roma, ItalyAges 18–60 - NCT06666049Recruiting
Ultrasound test on the stomach before surgery in patients taking GLP-1 drugs
This trial uses a stomach ultrasound (called gastric POCUS) to check if your stomach is empty before surgery. It is for patients taking GLP-1 medications (like Ozempic, Wegovy, or similar) to help make sure it is safe to proceed with anesthesia.
Madrid, MadridAges 18–90 - NCT06891287RecruitingPhase 1
Testing an oral GLP-1/2 capsule in healthy volunteers
This study tests a new oral capsule that delivers a medicine called PG-102, which is a dual GLP-1/2 agonist (similar to drugs used for diabetes and weight loss). It is for healthy volunteers to see how the body handles the medicine. The study has two parts: one for people with a lower BMI and one for people with a higher BMI (over 30).
Melbourne, VictoriaAges 18–65 - NCT05663515Recruiting
Checks pancreatic cancer risk after starting exenatide in type 2 diabetes
This study looks at whether starting exenatide (a type 2 diabetes medicine) is linked to a higher or lower risk of pancreatic cancer compared with other similar diabetes medicines. It uses people’s prescription and medical record history to compare risks over time.
CopenhagenAges 18–99 - NCT07234916Enrolling by invitation
Multivitamins for people starting weight-loss injections
This trial tests whether a multivitamin can help people on the weight-loss injection Tirzepatide maintain healthy vitamin levels. If you're using this injection and meet the other criteria, you may join.
AmersfoortAges 18–70 - NCT07760896Recruiting
Wellness program for people taking GLP-1 medications
This study combines a 30-day wellness program with your current GLP-1 medication to support your physical and emotional well-being. It is designed to help you build healthy habits and feel your best.
The Colony, TexasAges 18 years+ - NCT07633639Recruiting
GLP-1 Medicine After Weight-Loss Surgery in Chinese Patients
This trial tests whether adding a GLP-1 medication (a type of diabetes and weight-loss drug) after weight-loss surgery helps patients with obesity and related health conditions like diabetes. Researchers want to see if combining surgery with this medicine works better than surgery alone.
BeijingAges 18–60 - NCT07627191RecruitingEarly Phase 1
GLP-1 drug plus standard chemo for first-line advanced cancers
This trial tests whether adding a GLP-1 receptor agonist (a drug used for diabetes and weight loss) to standard chemotherapy can help people with advanced pancreatic, colorectal, or liver cancer. It is for people who have not yet started treatment for their metastatic disease and have a BMI of 25 or higher.
Tucson, ArizonaAges 18–99
Common questions
- Are there clinical trials studying GLP-1 Receptor Agonists?
- Yes. Clin2 currently lists 54 recruiting studies that include GLP-1 Receptor Agonists, drawn from the U.S. registry and rewritten for real people so you can see what each is testing and who it's for.
- How do I know if I qualify for a GLP-1 Receptor Agonists trial?
- Each study lists its own eligibility criteria — rules about condition, age, and prior treatments. On every Clin2 trial page we explain these in plain language and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Is GLP-1 Receptor Agonists an approved treatment?
- A drug being studied in a trial may be investigational (still being tested) or already approved and being studied for a new use. Each study page explains what phase it's in. Clin2 does not provide medical advice — talk with your doctor about whether GLP-1 Receptor Agonists or a specific trial is right for you.
Related treatments
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. A drug appearing here is being studied in a trial and may be investigational. Talk with your doctor about whether a specific treatment or trial is right for you.